跳至主要内容
临床试验/CTIS2022-500933-10-00
CTIS2022-500933-10-00招募中1 期

Aspirin for the Prevention of Preeclampsia and Pregnancy outcomes in nulliparous women after Assisted Reproductive Technology.APPART trial - RC31/21/0337

Centre Hospitalier Universitaire De Toulouse0 个研究点目标入组 1,164 人开始时间: 2022年7月13日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
入组人数
1,164

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)

入选标准

  • Nulliparous women aged 18 years or more, Pregnancy following ART, including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), oocyte donation or intrauterine insemination with sperm donor, Singleton pregnancy, Evolutive pregnancy between 9 and 14 weeks of gestation, Women affiliated to a French Social Security Insurance or equivalent social protection, Written informed consent

排除标准

  • Major fetal abnormality, Regular treatment with aspirin (including antiphospholipid syndrome), Aspirin contraindications (allergy, von Willebrand disease, peptic ulceration, hemophilia), Women protected by law., Women included in another interventional study.

研究者

相似试验